DOCSLIB.ORG

Www .Alfa.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Www .Alfa.Com Bio 2013-14 Alfa Aesar North America Alfa Aesar Korea Uni-Onward (International Sales Headquarters) 101-3701, Lotte Castle President 3F-2 93 Wenhau 1st Rd, Sec 1, 26 Parkridge Road O-Dong Linkou Shiang 244, Taipei County Ward Hill, MA 01835 USA 467, Gongduk-Dong, Mapo-Gu Taiwan Tel: 1-800-343-0660 or 1-978-521-6300 Seoul, 121-805, Korea Tel: 886-2-2600-0611 Fax: 1-978-521-6350 Tel: +82-2-3140-6000 Fax: 886-2-2600-0654 Email: [email protected] Fax: +82-2-3140-6002 Email: [email protected] Email: [email protected] Alfa Aesar United Kingdom Echo Chemical Co. Ltd Shore Road Alfa Aesar India 16, Gongyeh Rd, Lu-Chu Li Port of Heysham Industrial Park (Johnson Matthey Chemicals India Toufen, 351, Miaoli Heysham LA3 2XY Pvt. Ltd.) Taiwan England Kandlakoya Village Tel: 866-37-629988 Bio Chemicals for Life Tel: 0800-801812 or +44 (0)1524 850506 Medchal Mandal Email: [email protected] www.alfa.com Fax: +44 (0)1524 850608 R R District Email: [email protected] Hyderabad - 501401 Andhra Pradesh, India Including: Alfa Aesar Germany Tel: +91 40 6730 1234 Postbox 11 07 65 Fax: +91 40 6730 1230 Amino Acids and Derivatives 76057 Karlsruhe Email: [email protected] Buffers Germany Tel: 800 4566 4566 or Distributed By: Click Chemistry Reagents +49 (0)721 84007 280 Electrophoresis Reagents Fax: +49 (0)721 84007 300 Hydrus Chemical Inc. Email: [email protected] Uchikanda 3-Chome, Chiyoda-Ku Signal Transduction Reagents Tokyo 101-0047 Western Blot and ELISA Reagents Alfa Aesar France Japan 2 allée d’Oslo Tel: 03(3258)5031 ...and much more 67300 Schiltigheim Fax: 03(3258)6535 France Email: [email protected] Tel: 0800 03 51 47 or +33 (0)3 8862 2690 Fax: 0800 10 20 67 or OOO “REAKOR” +33 (0)3 8862 6864 Nagorny Proezd, 7 Email: [email protected] 117 105 Moscow Russia 2013-14 Alfa Aesar China Tel: +7 495 640 3427 Room 1509 Fax: +7 495 640 3427 ext 6 CBD International Building Email: [email protected] No. 16 Yong’An Dong Li Chao Yang District, Beijing, China VWR Singapore Pte Ltd 100022 18 Gul Drive Tel: 800-810-6000 or 86 (010)-8567-8600 Singapore 629468 or 400 610 6006 Tel: +65 6505 0760 Bulk Sales: 800 810 6006 Fax: +65 6264 3780 Fax: 86 (010)-8567-8601 Email: [email protected] Email: [email protected] Introducing Alfa Aesar Bio Access the Latest Information www.alfa.com Alfa Aesar is pleased to introduce the Looking for new Our website provides easy latest addition to its complete range products? access to the following: of over 33,000 products. • Material Safety Data Sheets Want to check (MSDS) The new biochemical product range product availability? • Certificates of Analysis • Up-to-date product availability adds over 3,000 products to the • Current pricing and ability to existing offering, providing a more Need more information? request pricing quotations complete selection for all of your • Structure/substructure search research needs. Visit Other enhancements to the With a wide and continuously growing www.alfa.com site include: variety of materials for biological • Improved search function research including electrophoresis • Easy online shopping reagents, enzymes, signal transduction • Order tracking and history • Complete technical reagents and much more, Alfa Aesar information and literature now truly offers one stop chemical references shopping combined with unparalleled customer service. Visit www.alfa.com for the latest news and product availability Table of Contents Table of Contents _________________________________________________________________________________ I Key to Chemical Listings _________________________________________________________________________ II How to Order ____________________________________________________________________________________ III General Information _____________________________________________________________________________IV Terms of Sale ____________________________________________________________________________________ V Product Information _____________________________________________________________________________VI Product Safety - MSDS ___________________________________________________________________________VIII Bulk and Specialty Capabilities __________________________________________________________________IX Worldwide Catalogue Sales _____________________________________________________________________ X Alfa Aesar Product Lines ________________________________________________________________________ XII About Johnson Matthey _______________________________________________________________________ XIV Alfa Aesar Literature ____________________________________________________________________________ XV Periodic Table _________________________________________________________________________________ XVI Abbreviations and Codes ________________________________________________________________________ 1 PRODUCT CATEGORY INDEX _________________________________________________________ 3 ACS Reagents ____________________________________________________________________________ 3 Amino Acids and Derivatives ______________________________________________________________ 5 Antibiotics ________________________________________________________________________________ 9 Antibodies ______________________________________________________________________________ 11 Apoptosis Reagents _____________________________________________________________________ 12 Buffers __________________________________________________________________________________ 14 Carbohydrates and Derivatives __________________________________________________________ 23 Cell Culture Reagents ____________________________________________________________________ 25 Chiral Compounds ______________________________________________________________________ 27 Click Chemistry Reagents ________________________________________________________________ 29 Electrophoresis Reagents ________________________________________________________________ 30 Enzymes ________________________________________________________________________________ 38 Growth Factors __________________________________________________________________________ 40 Natural Products _________________________________________________________________________ 41 Nucleosides and Nucleotides ____________________________________________________________ 43 Peptides_________________________________________________________________________________ 47 Signal Transduction Reagents ____________________________________________________________ 51 Solvents, Acids and Bases ________________________________________________________________ 62 Stains, Dyes and Indicators _______________________________________________________________ 63 Vitamins _________________________________________________________________________________ 66 Western Blot and ELISA Reagents _________________________________________________________ 67 ALPHABETICAL CHEMICAL LISTING _________________________________________ 69 I www.alfa.com Bio Intro_GL.indd 1 8/13/2012 9:46:09 AM Key to Chemical Listings 1 2 7 4 J62011 A-7 hydrochloride 25mg [N-(10-Aminodecyl)-5-chloro-1-naphthalenesulfonamide hydrochloride] [79127-24-5], C20H29ClN2O2SùHCl, F.W. 433.44, Solid H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 12 Application(s):Calmodulin antagonist J60039 Abamectin, 97+% 1g 5 [Avermectin B1] 5g [71751-41-2], C48H72O14, F.W. 873.10, Powder,m.p. 150-155ø,Merck 14,2,UN2811, 9 MDL MFCD01769550 25g H:H300-H400-H332, P:P261-P301+P310-P321-P304+P340-P405-P501a8 Application(s): Interacts with GABA receptorsto cause chloride channel14 activation L137706 Abieticacid, tech.75% È 3 25g [514-10-3], C20H30O2, F.W. 302.45, Merck 14,7, EINECS 208-178-3, 100g BRN 2221451, MDL MFCD03423567, Ì 11 10 H:H315-H319-H335, P:P261-P305+P351+P338-P302+P352-P321-P405-P501a 13 1 Stock number 9 UN Dangerous Goods number 2 Product name and grade 10 Denotes substance is listed in Toxic Substance Control Act (TSCA) Sensitivity symbol inventory 3 (see abbreviations index) 11 Globally Harmonized System (GHS) 4 Unit size Pictograms 5 Alternative name(s) 12 Precautionary and Hazard Codes 6 Chemical Abstract Service 13 Chemical structure (CAS) number 14 EINECS (European Inventory of Existing 7 Molecular formula Chemical Substances) Number 8 Physical form F.W. Formula weight Merck Merck Index Number m.p. Melting point BRN Beilstein Registry number b.p. Boiling point Fieser Fieser’s Reagents reference f.p. Flash point RTECS Registry of Toxic Effects of d. Density in g/ml Chemical Substances reference Ë Refractive index MDL MDL number ¾ Optical rotation II Bio Intro_GL.indd 2 8/13/2012 9:46:10 AM How to Order TELEPHONE EMAIL Please have the following information [email protected] available when placing an order: for catalogue product orders and general inquiries Your customer number (if applicable). Billing and shipping addresses. [email protected] for technical inquiries Product stock number, size, and quantity for each item you wish to [email protected] order. for bulk and specialty inquiries Your purchase order number or We do not require a confirming purchase government/corporate credit card order. If you choose to send one, please number and expiration date. mark it clearly, “CONFIRMING ORDER” to avoid possible duplication. There is no INTERNET minimum order. We welcome all orders, www.alfa.com regardless of size. Our web catalogue features up-to-date prices and a user-friendly e-commerce Alfa Aesar is ISO 9001 and ISO 14001 system. Certified III www.alfa.com Bio Intro_GL.indd 3 8/13/2012 9:46:11 AM General Information ORDERING Customer
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Role of Citicoline in the Management of Traumatic Brain Injury
    pharmaceuticals Review Role of Citicoline in the Management of Traumatic Brain Injury Julio J. Secades Medical Department, Ferrer, 08029 Barcelona, Spain; [email protected] Abstract: Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI. Keywords: CDP-choline; citicoline; pharmacological neuroprotection; brain ischemia; traumatic brain injury; head injury Citation: Secades, J.J. Role of 1. Introduction Citicoline in the Management of Traumatic brain injury (TBI) is among the most devastating types of injury and can Traumatic Brain Injury. result in a different profile of neurological and cognitive deficits, and even death in the most Pharmaceuticals 2021, 14, 410.
    [Show full text]
  • FROM MELANCHOLIA to DEPRESSION a HISTORY of DIAGNOSIS and TREATMENT Thomas A
    1 FROM MELANCHOLIA TO DEPRESSION A HISTORY OF DIAGNOSIS AND TREATMENT Thomas A. Ban International Network for the History of Neuropsychopharmacology 2014 2 From Melancholia to Depression A History of Diagnosis and Treatment1 TABLE OF CONTENTS Introduction 2 Diagnosis and classifications of melancholia and depression 7 From Galen to Robert Burton 7 From Boissier de Sauvages to Karl Kahlbaum 8 From Emil Kraepelin to Karl Leonhard 12 From Adolf Meyer to the DSM-IV 17 Treatment of melancholia and depression 20 From opium to chlorpromazine 21 Monoamine Oxidase Inhibitors 22 Monoamine Re-uptake Inhibitors 24 Antidepressants in clinical use 26 Clinical psychopharmacology of antidepressants 30 Composite Diagnostic Evaluation of Depressive Disorders 32 The CODE System 32 CODE –DD 33 Genetics, neuropsychopharmacology and CODE-DD 36 Conclusions 37 References 37 INTRODUCTION Descriptions of what we now call melancholia or depression can be found in many ancient documents including The Old Testament, The Book of Job, and Homer's Iliad, but there is virtually 1 The text of this E-Book was prepared in 2002 for a presentation in Mexico City. The manuscript was not updated. 3 no reliable information on the frequency of “melancholia” until the mid-20th century (Kaplan and Saddock 1988). Between 1938 and 1955 several reports indicated that the prevalence of depression in the general population was below 1%. Comparing these figures, as shown in table 1, with figures in the 1960s and ‘70s reveals that even the lowest figures in the psychopharmacological era (from the 1960s) are 7 to 10 times greater than the highest figures before the introduction of antidepressant drugs (Silverman 1968).
    [Show full text]
  • Drug-Excipient Interaction and Its Importance in Dosage Form
    Journal of Applied Pharmaceutical Science 01 (06); 2011: 66-71 ISSN: 2231-3354 Drug-excipient interacti on and its importance in Received: 29-07-2011 Revised on: 02-08-2011 Accepted: 04-08-2011 dosage form development Nishath Fathima, Tirunagari Mamatha, Husna Kanwal Qureshi, Nandagopal Anitha and Jangala Venkateswara Rao ABSTRACT Excipients are included in dosage forms to aid manufacture, administration or absorption. Although considered pharmacologically inert, excipients can initiate, propagate or participate in Nishath Fathima, Tirunagari chemical or physical interactions with drug compounds, which may compromise the effectiveness Mamatha, Husna Kanwal Qureshi, of a medication. Exicipients are not exquisitely pure. Even for the most commonly used excipients, Nandagopal Anitha and Jangala it is necessary to understand the context of their manufacture in order to identify potential active pharmaceutical ingredients interactions with trace components. Chemical interactions can lead to Venkateswara Rao Sultan-Ul-Uloom College of Pharmacy, degradation of the active ingredient, thereby reducing the amount available for therapeutic effect. Physical interactions can affect rate of dissolution, uniformity of dose or ease of administration. Banjara Hills, Hyderabad - 500034, A.P., India. Key words: Excipient, Drug, Interaction, Physical, Chemical. INTRODUCTION Pharmaceutical dosage form is a combination of active pharmaceutical ingredients (API) and excipients. Excipients are included in dosage forms to aid manufacture, administration or absorption (Crowley and Martini).The ideal excipients must be able to fulfill the important functions i.e. dose, stability and release of API from the formulation. Although considered pharmacologically inert, excipients can initiate, propagate or participate in chemical or physical interactions with drug compounds, which may compromise the effectiveness of a medication.
    [Show full text]
  • Inhibitory Effects of Gossypol, Gossypolone, and Apogossypolone on a Collection of Economically Important Filamentous Fungi Jay E
    Article pubs.acs.org/JAFC Inhibitory Effects of Gossypol, Gossypolone, and Apogossypolone on a Collection of Economically Important Filamentous Fungi Jay E. Mellon,*,† Carlos A. Zelaya,‡ Michael K. Dowd,† Shannon B. Beltz,† and Maren A. Klich† † Southern Regional Research Center, Agricultural Research Service, U.S. Department of Agriculture, 1100 Robert E. Lee Boulevard, New Orleans, Louisiana 70124, United States ‡ Department of Chemistry, University of New Orleans, New Orleans, Louisiana 70148, United States ABSTRACT: Racemic gossypol and its related derivatives gossypolone and apogossypolone demonstrated significant growth inhibition against a diverse collection of filamentous fungi that included Aspergillus flavus, Aspergillus parasiticus, Aspergillus alliaceus, Aspergillus fumigatus, Fusarium graminearum, Fusarium moniliforme, Penicillium chrysogenum, Penicillium corylophilum, and Stachybotrys atra. The compounds were tested in a Czapek agar medium at a concentration of 100 μg/mL. Racemic gossypol and apogossypolone inhibited growth by up to 95%, whereas gossypolone effected 100% growth inhibition in all fungal isolates tested except A. flavus. Growth inhibition was variable during the observed time period for all tested fungi capable of growth in these treatment conditions. Gossypolone demonstrated significant aflatoxin biosynthesis inhibition in A. flavus AF13 (B1, 76% inhibition). Apogossypolone was the most potent aflatoxin inhibitor, showing greater than 90% inhibition against A. flavus and greater than 65% inhibition against
    [Show full text]
  • DNA Modifications in Models of Alcohol Use Disorders
    Alcohol 60 (2017) 19e30 Contents lists available at ScienceDirect Alcohol journal homepage: http://www.alcoholjournal.org/ DNA modifications in models of alcohol use disorders * Christopher T. Tulisiak a, R. Adron Harris a, b, Igor Ponomarev a, b, a Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, 2500 Speedway, A4800, Austin, TX 78712, USA b The College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1900, Austin, TX 78712, USA article info abstract Article history: Chronic alcohol use and abuse result in widespread changes to gene expression, some of which Received 2 September 2016 contribute to the development of alcohol-use disorders (AUD). Gene expression is controlled, in part, by a Received in revised form group of regulatory systems often referred to as epigenetic factors, which includes, among other 3 November 2016 mechanisms, chemical marks made on the histone proteins around which genomic DNA is wound to Accepted 5 November 2016 form chromatin, and on nucleotides of the DNA itself. In particular, alcohol has been shown to perturb the epigenetic machinery, leading to changes in gene expression and cellular functions characteristic of Keywords: AUD and, ultimately, to altered behavior. DNA modifications in particular are seeing increasing research Alcohol fi Epigenetics in the context of alcohol use and abuse. To date, studies of DNA modi cations in AUD have primarily fi fi fi DNA methylation looked at global methylation pro les in human brain and blood, gene-speci c methylation pro les in DNMT animal models, methylation changes associated with prenatal ethanol exposure, and the potential DNA hydroxymethylation therapeutic abilities of DNA methyltransferase inhibitors.
    [Show full text]
  • A Single-Label Phenylpyrrolocytidine Provides a Molecular Beacon-Like Response Reporting HIV-1 RT Rnase H Activity Alexander S
    1048–1056 Nucleic Acids Research, 2010, Vol. 38, No. 3 Published online 20 November 2009 doi:10.1093/nar/gkp1022 A single-label phenylpyrrolocytidine provides a molecular beacon-like response reporting HIV-1 RT RNase H activity Alexander S. Wahba1, Abbasali Esmaeili2, Masad J. Damha1 and Robert H. E. Hudson3,* 1Department of Chemistry, McGill University, Montreal, QC, H3A 2K6 Canada, 2Department of Chemistry, University of Birjand, Birjand, Iran and 3Department of Chemistry, University of Western Ontario, London, ON, N6A 5B7 Canada Downloaded from https://academic.oup.com/nar/article/38/3/1048/3112336 by guest on 27 September 2021 Received August 15, 2009; Revised and Accepted October 19, 2009 ABSTRACT identified as a potential target for antiretroviral therapy as it is required for virus infectivity (3); yet there are no 6-Phenylpyrrolocytidine (PhpC), a structurally con- antiRNase H agents in clinical use. Few inhibitors of HIV- servative and highly fluorescent cytidine analog, 1 RNase H were identified until the transition of testing was incorporated into oligoribonucleotides. The methods from gel-based techniques to fluorescent assays PhpC-containing RNA formed native-like duplex amenable to high-throughput screening (HTS) (4–8). The structures with complementary DNA or RNA. The most widely used assay was developed by Parniak and co- PhpC-modification was found to act as a sensitive workers (6) and utilizes a two label, molecular beacon reporter group being non-disruptive to structure and strategy (9) in which the RNA strand is labeled with a 0 the enzymatic activity of RNase H. A RNA/DNA 3 -terminal fluorophore (fluorescein, F) and a DNA 0 hybrid possessing a single PhpC insert was an strand with a quencher (dabcyl, Q) at the 5 -terminus excellent substrate for HIV-1 RT Ribonuclease H (Scheme 1).
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Gossypol Decreased Cell Viability and Down-Regulated the Expression of A
    www.nature.com/scientificreports OPEN Gossypol decreased cell viability and down‑regulated the expression of a number of genes in human colon cancer cells Heping Cao 1*, Kandan Sethumadhavan1, Fangping Cao2 & Thomas T. Y. Wang3 Plant polyphenol gossypol has anticancer activities. This may increase cottonseed value by using gossypol as a health intervention agent. It is necessary to understand its molecular mechanisms before human consumption. The aim was to uncover the efects of gossypol on cell viability and gene expression in cancer cells. In this study, human colon cancer cells (COLO 225) were treated with gossypol. MTT assay showed signifcant inhibitory efect under high concentration and longtime treatment. We analyzed the expression of 55 genes at the mRNA level in the cells; many of them are regulated by gossypol or ZFP36/TTP in cancer cells. BCL2 mRNA was the most stable among the 55 mRNAs analyzed in human colon cancer cells. GAPDH and RPL32 mRNAs were not good qPCR references for the colon cancer cells. Gossypol decreased the mRNA levels of DGAT, GLUT, TTP, IL families and a number of previously reported genes. In particular, gossypol suppressed the expression of genes coding for CLAUDIN1, ELK1, FAS, GAPDH, IL2, IL8 and ZFAND5 mRNAs, but enhanced the expression of the gene coding for GLUT3 mRNA. The results showed that gossypol inhibited cell survival with decreased expression of a number of genes in the colon cancer cells. Abbreviations DMSO Dimethylsulfoxide LPS Lipopolysaccharides MTT 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide TTP Tristetraprolin ZFP36 Zinc fnger protein 36 Gossypol is a plant polyphenol with a highly colored yellow pigment (Fig.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • SUMMARY of PARTICULARLY HAZARDOUS SUBSTANCES (By
    SUMMARY OF PARTICULARLY HAZARDOUS SUBSTANCES (by alpha) Key: SC -- Select Carcinogens RT -- Reproductive Toxins AT -- Acute Toxins SA -- Readily Absorbed Through the Skin DHS -- Chemicals of Interest Revised: 11/2012 ________________________________________________________ ___________ _ _ _ _ _ _ _ _ _ _ _ ||| | | | CHEMICAL NAME CAS # |SC|RT| AT | SA |DHS| ________________________________________________________ ___________ | _ | _ | _ | _ | __ | | | | | | | 2,4,5-T 000093-76-5 | | x | | x | | ABRIN 001393-62-0 | | | x | | | ACETALDEHYDE 000075-07-0 | x | | | | | ACETAMIDE 000060-35-5 | x | | | | | ACETOHYDROXAMIC ACID 000546-88-3 ||x| | x | | ACETONE CYANOHYDRIN, STABILIZED 000075-86-5 | | | x | | x | ACETYLAMINOFLUORENE,2- 000053-96-3 | x | | | | | ACID MIST, STRONG INORGANIC 000000-00-0 | x | | | | | ACROLEIN 000107-02-8 | | x | x | x | | ACRYLAMIDE 000079-06-1 | x | x | | x | | ACRYLONITRILE 000107-13-1 | x | x | x | x | | ACTINOMYCIN D 000050-76-0 ||x| | x | | ADIPONITRILE 000111-69-3 | | | x | | | ADRIAMYCIN 023214-92-8 | x | | | | | AFLATOXIN B1 001162-65-8 | x | | | | | AFLATOXIN M1 006795-23-9 | x | | | | | AFLATOXINS 001402-68-2 | x | | x | | | ALL-TRANS RETINOIC ACID 000302-79-4 | | x | | x | | ALPRAZOMAN 028981-97-7 | | x | | x | | ALUMINUM PHOSPHIDE 020859-73-8 | | | x | | x | AMANTADINE HYDROCHLORIDE 000665-66-7 | | x | | x | | AMINO-2,4-DIBROMOANTHRAQUINONE 000081-49-2 | x | | | | | AMINO-2-METHYLANTHRAQUINONE, 1- 000082-28-0 | x | | | | | AMINO-3,4-DIMETHYL-3h-IMIDAZO(4,5f)QUINOLINE,2- 077094-11-2 | x | | | | | AMINO-3,8-DIMETHYL-3H-IMIDAZO(4,5-f)QUINOXALINE,
    [Show full text]
  • Thapsigargin—From Traditional Medicine to Anticancer Drug
    International Journal of Molecular Sciences Review Thapsigargin—From Traditional Medicine to Anticancer Drug Agata Jaskulska 1,2, Anna Ewa Janecka 2 and Katarzyna Gach-Janczak 2,* 1 Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] 2 Department of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-272-57-10 Abstract: A sesquiterpene lactone, thapsigargin, is a phytochemical found in the roots and fruits of Mediterranean plants from Thapsia L. species that have been used for centuries in folk medicine to treat rheumatic pain, lung diseases, and female infertility. More recently thapsigargin was found to be a potent cytotoxin that induces apoptosis by inhibiting the sarcoplasmic/endoplasmic reticu- lum Ca2+ ATPase (SERCA) pump, which is necessary for cellular viability. This biological activity encouraged studies on the use of thapsigargin as a novel antineoplastic agent, which were, however, hampered due to high toxicity of this compound to normal cells. In this review, we summarized the recent knowledge on the biological activity and molecular mechanisms of thapsigargin action and advances in the synthesis of less-toxic thapsigargin derivatives that are being developed as novel anticancer drugs. Keywords: thapsigargin; cytotoxin; anticancer activity; sarcoplasmic/endoplasmic reticulum Ca2+ ATPase; unfold protein response; apoptosis; prodrug; prostate-specific antigen; prostate-specific membrane antigen; mipsagargin 1. Introduction Citation: Jaskulska, A.; Janecka, A.E.; Thapsigargin (Tg), a guaianolide-type sesquiterpene lactone, is abundant in the com- Gach-Janczak, K. Thapsigargin—From mon Mediterranean weed Thapsia garganica (Apiaceae), known as “deadly carrot” due to Traditional Medicine to Anticancer its high toxicity to sheep and cattle.
    [Show full text]